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Abstract 
Purpose: Glaucoma is the leading cause of irreversible blindness worldwide. Primary open 
angle glaucoma (POAG) is the most common sub-type. We recently reported association of 
genetic variants at chromosomal loci, 1q24 and 9p21, with POAG. In this study we 
determined association of the most significantly associated single nucleotide polymorphism 
(SNP) rs4656461, at 1q24 near the TMCO1 gene, with the clinical parameters related to 
glaucoma risk and diagnosis, and determined ocular expression and sub-cellular localisation 
of the human TMCO1 protein to understand the mechanism of its involvement in POAG.  
Methods: Association of SNP rs4656461 with five clinical parameters was assessed in 1420 
POAG cases using linear regression. The TMCO1 gene was screened for mutations in 95 
cases with a strong family history and advanced disease. Ocular expression and sub-cellular 
localisation of the TMCO1 protein were determined by immunolabelling and as GFP-fusion. 
Results: The data suggest that individuals homozygous for the rs4656461 risk allele (GG) are 
4-5 years younger at diagnosis than non-carriers of this allele. Our data demonstrate 
expression of the TMCO1 protein in most tissues in the human eye including the trabecular 
meshwork and retina. However, the sub-cellular localisation differs from that reported in 
other studies. We demonstrate that the endogenous protein localises to the cytoplasm and 
nucleus in vivo and ex vivo. In the nucleus, the protein localises to the nucleoli. 
Conclusions: This study shows a relationship between genetic variation in and around 
TMCO1 with age at diagnosis of POAG and provides clues to the potential cellular function/s 
of this gene. 
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Introduction 
Glaucoma refers to a group of neurodegenerative ocular diseases united by a clinically 
characteristic optic neuropathy. Open-Angle Glaucoma (OAG) is common, with a prevalence 
of around 3% in people over 50 years of age1. The disease has long been known to have a 
genetic component. First-degree relatives of affected patients exhibit a 9-fold increased 
relative risk of developing primary OAG (POAG) compared with the general population2. 
The Glaucoma Inheritance Study in Tasmania (GIST) revealed that a positive family history 
is found in approximately 60% of cases of POAG when family members are examined3, and 
the disease is more severe in people with a family history of glaucoma, compared to those 
with “sporadic” glaucoma4. Mutations in the myocilin gene (MYOC) are the most common 
reported genetic cause of POAG and account for around 3%-5% of cases5. Mutations in 
optineurin (OPTN) and WDR36 genes have also been implicated5. Recent genome-wide 
association studies have identified common variants at several new genetic loci are associated 
with POAG including CAV1 and CAV2 on chromosome 7q31, CDKN2B-AS1, CDKN2A and 
CDKN2B on 9p21, and TMCO1 on 1q246, 7. The mechanism of disease association is not yet 
clear for any of these genetic associations and very little is known about the normal function 
of TMCO1 and its role in the eye.  
The TMCO1 gene encodes the Transmembrane and coiled-coil domains-1 protein which 
belongs to the DUF841 superfamily of unknown function8. The gene is located ~6Mb 
upstream of the known POAG gene MYOC on chromosome 1. The protein sequence is highly 
conserved across mammalian species9. The gene is expressed in a variety of human adult and 
fetal tissues at varying levels9, including ocular tissues6. Immunohistochemistry revealed 
cytoplasmic labelling in the rat retinal ganglion cell layer6. The GFP (green fluorescent 
protein)-fusion of TMCO1 has been reported to localise to endoplasmic reticulum and Golgi 
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apparatus in COS7 cells10, and to the mitochondria in porcine PK-15 cells8. These reports 
suggest that the sub-cellular localisation of the protein may differ depending on cell type. A 
homozygous frame-shift mutation in the TMCO1 gene has been shown to cause a rare 
recessive syndrome in the Amish consisting of craniofacial dysmorphism, skeletal anomalies 
and mental retardation, now known as ‘TMCO1 defect syndrome’ 9. There are no reports of 
glaucoma in this family. Our recent study failed to find any coding mutations in POAG 
patients carrying two risk haplotypes at the TMCO1 locus, indicating that coding mutations in 
TMCO1 are unlikely to account for the association observed with POAG6.  
The most associated SNP at the 1q24 locus (rs4656461) is just 3’ to TMCO1 and the second 
ranked SNP rs7518099 is within intron 2 of this gene and is in almost complete linkage 
disequilibrium with rs4656461. In addition, the highest ranked imputed SNP, rs7524755 is 
within the 3’ UTR of TMCO16. All the associated SNPs are within the same linkage 
disequilibrium block as TMCO1 with no other transcripts in the block. The common 
haplotype across the gene, which is efficiently tagged by the most associated SNP, increases 
the risk of POAG. This association was discovered in a cohort of POAG patients with severe 
blinding disease, replicated in a second similar cohort and another cohort with less-severe 
glaucoma6. From these data, however, it is as yet unclear whether TMCO1 genetic variation 
can be used to pinpoint a distinct sub-type of POAG or if TMCO1 mutations might contribute 
to some cases of familial OAG.  
In the present study, we further investigated the TMCO1 gene for association with clinical 
traits relevant to glaucoma risk and diagnosis, and screened for mutations in patients with a 
strong family history of POAG. In addition, we investigated the detailed expression pattern of 
TMCO1 in human eye and determined the sub-cellular localisation of the protein in relevant 
cell lines and in vivo in the eye.  
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Methods 
Patient recruitment and data collection 
Participants were drawn from the Australian & New Zealand Registry of Advanced Glaucoma 
(ANZRAG), the GIST, the Blue Mountains Eye Study (BMES) and patients attending the eye 
clinic at Flinders Medical Centre (Adelaide, Australia). All participants were included in the 
study reporting the association of TMCO1 with POAG and the cohorts are described in more 
detail in that report6. This cohort was also examined for genotype-phenotype relationships at 
another POAG locus on chromosome 9p21 in an independent study11. POAG was defined by 
concordant findings of typical glaucomatous visual field defects on the Humphrey 24-2 test 
(Humphrey 30-2 test was used in BMES), with corresponding optic disc rim thinning, 
including an enlarged cup-disc ratio (≥ 0.7), or cup-disc ratio asymmetry (≥0.2) between the 
two eyes. Clinical exclusion criteria were: i) pseudoexfoliation or pigmentary glaucoma, ii) 
angle closure or mixed mechanism glaucoma, iii) secondary glaucoma due to aphakia, 
rubella, rubeosis or inflammation, iv) infantile glaucoma, and v) glaucoma in the presence of 
a known associated syndrome. Available clinical data were extracted from each study, and 
included sex, age at diagnosis, highest recorded intraocular pressure (IOP), visual field mean 
deviation, vertical cup:disc ratio, central corneal thickness and genotype at SNP rs4656461. 
Where full clinical records were available, age at diagnosis was defined as the first occasion 
on which the patient demonstrated definitive glaucomatous visual field loss, as defined in the 
inclusion criteria. When this information was not available, the chronological age of the 
patient at the initiation of treatment for glaucoma (eye drops, laser or surgery) was taken. All 
participants provided written informed consent. Approval was obtained from the Human 
Research Ethics Committees (HRECs) of Southern Adelaide Health Service/Flinders 
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University, University of Tasmania and The Royal Victorian Eye and Ear Hospital. All 
participants were screened for mutations in the MYOC gene by direct sequencing of exon 3 on 
an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) with 
BigDye Terminators (Applied Biosystems, Foster City, CA, USA) according to standard 
protocols. Primer sequences are available on request. 
Genotyping and association analysis 
Genotyping of the rs4656461 SNP was conducted as previously reported6. Briefly, samples 
originally included in the discovery phase of the genome-wide association scan were 
genotyped on Omni1 SNP arrays (Illumina Inc, San Diego, CA, USA) while those included in 
the replication phase were typed with iPlex Gold chemistry on an Autoflex Mass 
Spectrometer (Sequenom Inc. San Diego, CA, USA). Each clinical trait was assessed for 
association with SNP rs4656461 (the glaucoma-associated SNP tagging the at-risk haplotype 
as reported previously6) using linear regression under a dominant genetic model. This model 
was chosen to maintain statistical power because this SNP is relatively rare (minor allele 
frequency ~12%) and only 24 homozygous patients were observed in our cohort. SNP 
genotypes were coded as carriers of the POAG risk allele (GA or GG genotype) and non-
carriers (AA genotype), and analysed in the model as a categorical variable. The assumptions 
of linear regression were met. A p-value of 0.01 was required to account for the multiple 
testing of 5 traits (highest recorded IOP, age at diagnosis, mean deviation, cup:disc ratio and 
central corneal thickness). Significantly associated traits were then assessed under 
multivariate analysis including each of the other traits as well as sex in the model. Analyses 
were conducted including and excluding patients with known MYOC mutations. All analyses 
were conducted using IBM-SPSS Statistics V19 (IBM Corp, Armonk, NY, USA). 
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Sequencing of the TMCO1 gene 
Ninety-five participants from the ANZRAG and GIST with advanced POAG (defined as best-
corrected visual acuity worse than 6/60 due to POAG, or a reliable 24-2 Visual Field with a 
mean deviation of worse than -22db or at least 2 out of 4 central fixation squares affected with 
a Pattern Standard Deviation of < 0.5%) and a strong family history of POAG were selected 
for re-sequencing of the protein coding regions of the TMCO1 gene. Family history was 
defined as three or more relatives diagnosed with glaucoma. This was self-reported in 
ANZRAG but determined by ophthalmic examination of extended families in GIST. Each 
exon and flanking intron of the TMCO1 gene was sequenced as previously described6. 
Sequences were compared to the TMCO1 reference sequence (GenBank Accession 
NM_019026) using Sequencher V4.10.1 (GeneCodes Corporation, Ann Arbor, MI, USA). 
Subcellular localisation 
A GFP-TMCO1 fusion construct was generated by cloning the open-reading frame of the 
protein in pEGFP-C1 (Clontech Laboratories, Inc, Mountain View, CA, USA). For this, 
TMCO1 cDNA was amplified from the human retina as previously described6 and cloned in-
frame with GFP at EcoRI and XbaI sites in the vector. In-frame cloning was confirmed by 
sequencing. Expression of the fusion protein was demonstrated in transiently transfected 
HEK293A cells by Western blotting as previously described12 except that protein extraction 
was performed in RIPA buffer [10 mM HEPES pH7.5, 150 mM NaCl, 1% Triton X-100, 
0.5% sodium deoxycholate, 0.1% SDS, 2 mM EDTA, Protease Inhibitor Cocktail (Roche 
Diagnostics), 57 μM PMSF, 2 mM sodium orthovanadate, 10 mM sodium pyrophosphate and 
20 mM sodium fluoride]. For subcellular localisation, 3×105 SH-SY5Y human neuroblastoma 
cells were seeded onto glass coverslips in 6-well tissue culture plates. The cells were cultured 
in a 1:1 mixture of Dulbecco’s modified Eagle’s medium and Ham’s F12 medium (GIBCO, 
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Invitrogen Australia Pty Ltd, Mulgrave, Vic) supplemented with 10% fetal bovine serum and 
1% penicillin/streptomycin, in a humidified atmosphere at 37°C and 5% CO2. On the 
following day, the cells were transfected with either GFP-TMCO1 fusion construct or empty 
vector using Lipofectamine 2000 (Invitrogen Australia Pty Ltd) as per the manufacturer’s 
protocol. Approximately 48h post-transfection, the cells were incubated with 1µM BODIPY-
TR-Ceramide (Molecular Probes, Invitrogen Australia Pty Ltd) for 2h to label the golgi 
apparatus or with 0.25µM MitoTracker® Red CM-H2XRos (Molecular Probes) for 30 min to 
label mitochondria. After incubation, the cells were washed several times with phosphate 
buffered saline (PBS), fixed in 4% paraformaldehyde/PBS, and mounted on microscope slides 
in ProLong® Gold antifade reagent with DAPI (Molecular Probes). Confocal microscopy was 
performed on a Leica TCS SP5 inverted Spectral confocal microscope equipped with LAS AF 
software.  
Immunolabelling 
For immunohistochemical labelling of the TMCO1 protein in human eye, the eye tissue was 
obtained from deceased donors through the Eye Bank of South Australia, following the 
guidelines of the Southern Adelaide Health Service/Flinders University HREC. The tissue 
was obtained within 12 hours of donor death and average donor age was 70 years. The tissue 
from donors without a history of ocular disease such as keratoconus, pterygium, refractive 
surgery, inflammation, tumor and glaucoma, was obtained. Specificity of the rabbit anti-
human TMCO1 antibody (Sigma-Aldrich, Pty Ltd, Castle Hill, NSW, Australia) used for 
immunolabelling was demonstrated in human optic nerve by Western blotting as previously 
described13. For immunolabelling, the eye tissue was fixed in buffered-formalin and 
embedded in paraffin. 4 µm thick paraffin embedded sections of the human eye were 
immunolabelled for the TMCO1 protein as previously described14 except for the following 
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variations. After hybridisation with the rabbit anti-human TMCO1 primary antibody (1:1000), 
the sections were hybridised with the NovoLink® Polymer complex reagent (Leica 
Microsystems, Bannockburn, IL, USA) and visualised by Chromogen substrate coloration 
(Dako, Glostrup, Denmark). Sections were counterstained with haematoxylin and mounted in 
DePeX (Merck KGaA, Darmstadt, Germany). Light microscopy was performed on an 
Olympus BX41 microscope attached with a digital DP20/DP70 camera using CellSens 
Standard Photography software (Olympus Corporation, Tokyo, Japan).  
Double immunofluorescent labelling in human eye sections was performed as previously 
described15. Visualisation of nucleolin, coilin and SC35 was achieved using a 3-step 
procedure (primary antibody, biotinylated secondary antibody, streptavidin-conjugated 
AlexaFluor 594), while TMCO1 was labelled by a 2-step procedure (primary antibody, 
secondary antibody conjugated to AlexaFluor 488). In brief, tissue sections were 
deparaffinized. Next, antigen retrieval was achieved by microwaving the sections in 10 mM 
citrate buffer (pH 6.0). Tissue sections were then blocked in PBS containing 3% normal horse 
serum and subsequently incubated overnight at room temperature in the appropriate 
combination of primary antibodies. On the following day, sections were incubated with 
biotinylated anti-mouse secondary antibody (1:250) for the 3-step procedure plus the anti-
rabbit secondary antibody conjugated to AlexaFluor 488 (1:250, Molecular Probes) for the 2-
step procedure for 30 min, followed by streptavidin-conjugated AlexaFluor 594 (1:500, 
Molecular Probes) for 1h. Sections were then mounted using anti-fade mounting medium and 
examined under a confocal fluorescence microscope. The following antibodies were used: 
rabbit anti-human TMCO1 (ARP49429, Aviva Systems Biology, San Diego, CA. USA), 
mouse anti-human nucleolin (ab13541, Abcam, Cambridge, MA, USA), mouse anti-human 
coilin (ab11822, Abcam), mouse anti-SC35 (ab11826 Abcam). 
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For immunolabelling of endogenous TMCO1 in SH-SY5Y cells, 3×105 cells were seeded 
onto glass coverslips in 6-well plates. Three days later, labelling was performed as previously 
described12. The cells were hybridised with the rabbit anti-TMCO1 primary antibody (1:1000; 
Sigma) followed by hybridisation with the Alexa Flour 488 conjugated anti-rabbit IgG 
secondary antibody (1:1000; Molecular Probes). For double labelling, the cells were 
hybridised with the anti-TMCO1 antibody and mouse anti-nucleolin monoclonal antibody 
(1:500; Abcam). The anti-TMCO1 antibody was detected with Alexa Flour 488 conjugated 
anti-rabbit IgG secondary antibody and anti-nucleolin with Alexa Fluor 594 conjugated anti-
mouse IgG secondary antibody (1:500; Molecular Probes). The single and double labelled 
cells were mounted, and confocal microscopy performed as described above.  
 
Results 
Characterisation of the glaucoma phenotype associated with TMCO1 genetic variants 
Genotype information for SNP rs4656461 and clinical characterisation of the disease were 
available for 1420 individuals. Descriptive statistics of each measured clinical trait are given 
in Table 1. For some individuals, the data for some of the clinical traits was not available. 
Each clinical trait was assessed for association with SNP rs4656461 (Table 2). Age at 
diagnosis was significantly decreased in carriers of the POAG risk allele (G) at this SNP 
(p=0.004). Vertical cup:disc ratio was increased (p=0.017); however, this result did not 
survive Bonferroni correction for the five traits assessed and the effect size estimate was 
small. Exclusion of 20 patients carrying pathogenic mutations in the MYOC gene did not 
significantly alter the results. 
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To explore the relationship between SNP rs4656461 and age at diagnosis further, multiple 
linear regression was conducted, including additional clinical covariates in the model. 
Carriers of POAG risk alleles were diagnosed over 3 years earlier than patients with no risk 
alleles at this locus (p=0.024, Table 3). Highest recorded IOP also contributed significantly to 
the model with a higher IOP also leading to a slightly younger age at diagnosis (0.26 years, 
p=0.0002). Exclusion of patients with MYOC mutations improved the significance of the 
observed association with age at diagnosis. The B coefficient increased to -3.54 (p=0.011), 
indicating a slightly stronger relationship when these generally young age at diagnosis 
patients were removed. In the multivariate analysis, the association with IOP was still 
significant but slightly attenuated with the exclusion of MYOC carriers (B=-0.243, p=0.001). 
The mean age at diagnosis by genotype of rs4656461 is shown in Table 4. Consistent with the 
multivariate model, the mean age at diagnosis was decreased 2-3 years for each POAG risk 
allele in the total cohort. This is also evident when MYOC carriers are excluded. No 
significant association of rs4656461 with age at diagnosis was observed in the MYOC 
mutation carriers (ANOVA p=0.971). The borderline association with cup:disc ratio was not 
significant after inclusion of IOP, age at diagnosis, CCT and sex in the model (p=0.066, data 
not shown). 
Of 320 carriers of the rs4546461 risk allele (G), 60% (n=195) reported a family history of 
glaucoma. By comparison only 51% of non-carriers (331 of 643) reported a family history. 
This demonstrates an enrichment for family history of glaucoma amongst TMCO1 risk allele 
carriers (OR=1.47, 95%CI [1.12-1.93], p=0.007). In order to identify heritable rare variants 
that may contribute to the POAG phenotype, 95 patients with a strong family history of the 
disease were selected for re-sequencing of the gene. Although several previously reported 
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SNPs, present in the general population, were observed, no novel pathogenic mutations were 
detected in the protein coding regions of the gene in this subset of individuals. 
Sub-cellular localisation of TMCO1 and expression in mammalian eye 
To explore the subcellular localisation of the TMCO1 protein in cell lines relevant to the 
retina, GFP-TMCO1 fusion was transiently expressed in SH-SY5Y human neuroblastoma 
cells. Prior to that, expression of the fusion protein by the fusion construct in HEK293A cells 
was demonstrated by Western blotting (Figure 1A). In SH-SY5Y cells the fusion protein was 
found either uniformly distributed in the cytoplasm or concentrated around the nucleus or 
aggregated on one side of the nucleus (Figure 1B and data not shown). However, labelling of 
these cells with the golgi apparatus or mitochondrial marker did not show any co-localisation 
of the protein with either organelle (Figure 1B, top and middle panels). In GFP expressing 
control cells, the protein distributed throughout the cell and, as expected, did not co-localise 
with the golgi apparatus or mitochondria (Figure 1B, bottom panels). A similar localisation 
pattern of the GFP-TMCO1 fusion was seen in SRA 01/04 lens epithelial cells (data not 
shown).  
For determining expression and in vivo localisation of TMCO1 in the human eye, 
immunolabelling was performed in human ocular sections with the anti-TMCO1 antibody. 
Specificity of the antibody was demonstrated by detection of the expected ~21 kDa protein 
band in human optic nerve by Western blotting (Figure 2A). In human ocular sections, 
positive immunolabelling was observed in the iridocorneal angle, trabecular meshwork, 
ciliary body and retina (Figure 2B). In the trabecular meshwork, positive immunolabelling 
was primarily seen as 1-2 dots in the nucleus along with cytoplasmic labelling (Figure 2B-B 
and C). A similar pattern of nuclear labelling and cytoplasmic labelling was observed in cells 
in the ciliary body (Figure 2B-D and E). In the retina, dot-like nuclear and positive 
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cytoplasmic labelling was observed in the photoreceptor, bipolar and ganglion cell layers 
(Figure 2B-F and G). Cytoplasmic labelling was more prominent in the photoreceptor outer 
segments and ganglion cells than in bipolar cells. These data suggest that the TMCO1 protein 
is expressed in most ocular tissues and corroborate the previous finding of TMCO1 transcript 
in these tissues6. Cytoplasmic labelling correlates with that previously reported by us in rat 
retinal ganglion cells6. Nuclear and cytoplasmic labelling of the protein in the eye indicates 
that TMCO1 is likely a multifunctional protein with functions both in the cytoplasm and 
nucleus. However, as all nuclear proteins are produced in the cytoplasm and then translocated 
to the nucleus, it is possible that the cytoplasmic labelling of TMCO1 represents its 
production rather than function in this compartment. 
Next, we investigated the identity of the discrete sub-nuclear regions immunopositive for 
TMCO1 in the cells in ocular tissues. We hypothesised that these sub-nuclear regions either 
represent nucleoli, Cajal body or nuclear speckles. Nucleolin is a protein that frequently 
localises to the nucleoli and is therefore used as a nucleolar marker16. However it is also 
known to localise to the perinucleolar compartment17. The coilin protein markers the Cajal 
body and SC35 the speckles in the nucleus18. To determine whether TMCO1 localises to the 
nucleolus, Cajal body or speckles in the cells in ocular tissues, we individually assessed its 
co-localisation with nucleolin, coilin and SC35 proteins. Double labelling with the anti-
TMCO1 and anti-nucleolin antibodies revealed co-localisation of TMCO1 and nucleolin in 
the nucleus to discrete sub-cellular regions in the cells in human ocular sections. 
Representative co-localisation in the retinal ganglion cells can be seen in Figure 3. The two 
proteins were also observed in the cytoplasm in ocular cells where they co-localised with each 
other. However, double labelling with anti-TMCO1 and anti-coilin antibodies and with anti-
TMCO1 and anti-SC35 antibodies revealed that TMCO1 did not co-localise with coilin or 
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SC35 in the nucleus or cytoplasm (Figure 3). These data indicate that sub-nuclear TMCO1 in 
the cells in ocular tissues localises to nucleoli. 
Finally, we investigated whether endogenous TMCO1 in SH-SY5Y cells mimics in vivo 
localisation in the human eye. Immunolabelling with the anti-TMCO1 antibody revealed 
distribution of the protein in the cytoplasm and nucleus in a punctate fashion in these cells 
(Figure 4, bottom left panel). The signal was stronger in the nucleus compared to the 
cytoplasm. In addition, in a small proportion of cells, instead of being evenly distributed in 
the nucleus the protein was concentrated to discrete sub-nuclear regions as seen in vivo in the 
eye (Figure 4, top left panel). To determine if these TMCO1 positive sub-nuclear regions 
represent nucleoli, we assessed co-localisation of TMCO1 with nucleolin in SH-SY5Y cells. 
Double labelling with the anti-TMCO1 and anti-nucleolin antibodies revealed TMCO1 
localisation as described above, and localisation of nucleolin to discrete sub-nuclear regions 
(Figure 4, second column). In cells with sub-nuclear localisation of TMCO1, the protein 
showed complete co-localisation with nucleolin in some cells (Figure 4, top row), as observed 
in vivo, and exhibited incomplete co-localisation in other cells (Figure 4, middle row). In cells 
where TMCO1 was evenly distributed in the nucleus, the protein did not co-localise with 
nucleolin (Figure 4, bottom row). Double labelling with anti-TMCO1 and anti-coilin and with 
anti-TMCO1 and anti-SC35 antibodies showed that TMCO1 does not co-localise with coilin 
or SC35 in SH-SY5Y cells (data not shown). From these data TMCO1 appears to shuttle 
between the cytoplasm and nucleus and transiently localise to the nucleolus or the 
perinucleolar compartment.  
Discussion  
Genetic variation in and around the TMCO1 gene at 1q24 has been shown to be associated 
with POAG6. The function of this gene is not well elucidated and it is not yet known how this 
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gene contributes to glaucoma. This study has shown that POAG patients carrying the 
glaucoma risk alleles at SNP rs4656461 tend to be diagnosed with the disease several years 
earlier than patients without these alleles. However, this study was not able to show 
association of rs4656461 with IOP, cup:disc ratio, mean deviation or central corneal 
thickness. Thus, apart from a slightly earlier onset, TMCO1-related glaucoma does not appear 
to be a clinically distinct sub-type of POAG. These SNPs may be severity factors for POAG, 
which could influence the age at onset of disease. This idea is consistent with our previous 
work showing an increased odds ratio for association in patients with blinding POAG 
compared to patients with less severe POAG6. In patients with a family history of advanced 
glaucoma, there may be a tendency for increased monitoring and thus earlier diagnosis 
(pseudo-anticipation). This phenomenon may contribute to the current findings given the 
observation of an increased family history in risk allele carriers. This is a limitation of our 
approach, however, the same association with age of diagnosis was not observed at the 
CDKN2B-AS1 gene in this same cohort 11. Thus, we believe pseudo-anticipation is not having 
a major effect on the current findings.  
MYOC glaucoma is also well known to have a younger age of onset, but within this small 
group of patients the TMCO1 gene does not appear to be modifying this risk although the 
power of this analysis is minimal in this cohort with a limited number of participants carrying 
both MYOC mutations and TMCO1 risk alleles. The inclusion of patients with MYOC 
mutations in the current analysis also does not account for the younger age of diagnosis 
observed in TMCO1 risk allele carriers. The methods used for the collection of age at 
diagnosis data do have some limitations. Where complete clinical records were not available 
to confirm the age of definitive glaucomatous visual loss, self reported age at treatment 
initiation was used as a surrogate. However, it is unlikely that any bias introduced by this 
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limitation would be distributed differently across genotypes. Nevertheless, replication of the 
observed association in independent POAG cohorts is required to confirm the current 
findings. 
By re-sequencing of 95 patients with a strong family history of POAG, coding variants do not 
appear responsible for the disease phenotype in these families deemed likely to have highly 
penetrant dominant mutations. This is not surprising given that the amino acid sequence of 
this protein is completely conserved between all mammals investigated to date9. This implies 
a crucial role for this ubiquitously expressed protein. The absence of coding variants in 
POAG patients in this study suggests genetic variation in regulatory elements may be 
responsible for the observed association signal. Further in-depth and functional analysis of the 
locus is required to determine this. 
As an initial step towards functional analysis of the TMCO1 gene, we determined sub-cellular 
localisation of the encoded protein and protein expression in the human eye. Expression of the 
protein in all the ocular tissues is consistent with its reported ubiquitous expression9. 
Localisation of the GFP-TMCO1 fusion in cultured mammalian cells in this study 
contradicted the previous reports. Iwamuro et al. reported localisation of the human TMCO1-
GFP fusion to the endoplasmic reticulum and golgi apparatus in COS-7 cells but did not 
determine co-localisation with the organelle specific markers10.  Zhang et al., however, 
reported localisation of the GFP fusion of porcine TMCO1 to mitochondria in PK-15 porcine 
kidney cells and co-localisation with the mitochondrial marker8. In this study, we observed 
neither co-localisation of human GFP-TMCO1 with the endoplasmic reticulum and golgi 
apparatus, nor mitochondria in cultured human neuroblastoma and lens epithelial cells. In 
addition, the fusion protein did not co-localise with the golgi apparatus or distribute to the 
endoplasmic reticulum in COS-7 cells under our experimental conditions (data not shown), 
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which further contradicts findings in these cells by Iwamuro et al10. Furthermore, we 
observed cytoplasmic and nuclear localisation as inclusions of endogenous TMCO1 in the 
human ocular tissues. In SH-SY5Y neuroblastoma cells also, endogenous TMCO1 was found 
in the cytoplasm and nucleus and in some cells as nuclear inclusions. Together, our data 
suggest that GFP-TMCO1 fusion localises differently than endogenous TMCO1. This may be 
because TMCO1 protein is smaller than GFP (~21 versus 28 kDa) thus the latter leads to 
aberrant localisation of the former or due to overexpression of the fusion protein. Grossly 
different localisation patterns of the GFP fusion and endogenous protein seen in this study 
highlight that ectopically expressed GFP fusions may not always reflect biological 
localisation of the protein of interest.  
The functional significance of the cytoplasmic localisation of endogenous TMCO1 is as yet 
unclear. However, the conspicuous sub-nuclear localisation in vivo in the human eye and ex 
vivo in some SH-SY5Y cells, and co-localisation with nucleolin is very interesting. Nucleolin, 
the major component of the nucleolus, also localises to the perinucleolar compartment, 
nucleoplasm, and the cell surface17, 19. The nucleolus is conventionally involved in ribosome 
biogenesis but also has non-conventional roles including regulation of tumor suppressor and 
oncogene activities, nuclear export and control of aging20. The perinucleolar compartment is 
associated with malignancy17. Interestingly, the CDKN2B gene and the antisense RNA gene 
CDKN2B-AS1 recently associated with POAG by us and others are involved in tumor 
suppression and cell-cycle regulation6, 21. From the present data it is not unreasonable to 
speculate that TMCO1 may also play a role in tumor suppression and/or cell-cycle regulation. 
Furthermore, involvement of the nucleolus in controlling aging and association of the risk 
allele of SNP rs4656461 near the TMCO1 gene with earlier age at diagnosis of glaucoma raise 
the possibility of a role of this gene in aging. In our view, this gene is likely involved in cell 
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cycle regulation in glaucoma. In conclusion, the present study provides clues to the potential 
cellular function/s of TMCO1 and shows a relationship between genetic variation in and 
around this gene with age at diagnosis of POAG. It also suggests that SH-SY5Y cells are a 
useful model for investigating TMCO1 function. Further longitudinal studies will investigate 
whether TMCO1 genotyping can predict severity or progression of glaucoma.  
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Table 1: Clinical characteristics of the cohort.  
Clinical trait N 
Mean±SD or 
%(n) 
Highest recorded IOP 
(mmHg) 
1275 26.5 ± 10.0 
Age at diagnosis (years) 1141 62.4 ± 14.0 
Mean deviation (dB) 658 -17.8 ± 9.4 
Cup:disc ratio 1146 0.87 ± 0.13 
Central corneal thickness 
(µm) 
693 518 ± 41 
Gender (% Male) 1389 46.6% (647) 
Abbreviations: IOP= intraocular pressure; SD = standard deviation 
 
Table 2: Association of SNP rs4656461 with each clinical trait under a dominant model.  
Clinical trait B 
Standard 
Error 
P-value 
Highest recorded IOP 0.07 0.60 0.908 
Age at diagnosis -2.56 0.88 0.004 
Mean deviation -0.58 0.77 0.465 
Cup:disc ratio 0.02 0.008 0.017 
Central corneal thickness -1.43 3.29 0.665 
p-value < 0.01 is considered significant. 
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Table 3: Multiple regression for age at diagnosis. R2=0.068.  
Clinical trait B 
Standard 
Error 
P-value 
Highest recorded IOP -0.26 0.07 0.0002 
Mean Deviation -0.02 0.09 0.841 
Cup:disc ratio 8.55 7.16 0.233 
Central corneal thickness -0.03 0.02 0.078 
Gender 1.78 1.36 0.193 
rs4656461 G allele carriers -3.13 1.39 0.024 
p-value < 0.01 is considered significant. 
 
 
Table 4: Mean age at diagnosis (years) by rs4656461 genotype. The G allele at this SNP is the 
risk allele for glaucoma. Analysis on MYOC mutation carriers and non-carriers is also shown. 
Stddev= Standard Deviation 
 All patients MYOC carriers Non-MYOC carriers 
Genotype N 
Mean 
age 
stddev N 
Mean 
age 
stddev N 
Mean 
age 
stddev 
AA 769 63.3 14.1 11 46.3 19.4 758 63.5 13.9 
AG 351 60.9 13.7 5 48.6 14.8 346 61.0 13.6 
GG 21 58.7 14.4 2 47.0 8.5 19 59.9 14.5 
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Figure legends 
Figure 1. A) Fusion protein encoded by the GFP-TMCO1 construct. Cell lysates from HEK 
293A cells transiently transfected with the fusion construct (GFP-TMCO1) or pEGFP-C1 
vector (GFP) were analysed by Western blotting with the anti-GFP antibody. The band of 
approximately 50 kDa seen in the TMCO1-GFP lane corresponds with the expected size of 
the fusion protein and that of approximately 28 kDa in the GFP lane corresponds with the size 
of GFP. The >28 kDa protein band seen in the TMCO1-GFP lane may represent fusion 
protein degradation. Molecular sizes of the protein standards are indicated in kilodaltons 
(kDa). B) GFP-TMCO1 fusion localisation in SH-SY5Y human retinoblastoma cells. Cells 
transiently transfected with the fusion construct (GFP-TMCO1) or pEGFP-C1 vector (GFP) 
(green channel) were either stained with BODIPY-TR-Ceramide for labelling the golgi 
apparatus (Golgi) or MitoTracker® Red CM-H2XRos for labelling mitochondria (Mito) (red 
channel), nuclei counterstained with DAPI (blue channel), and visualised by confocal 
microscopy. GFP-TMCO1 can be seen in the cytoplasm (green). However, in overlayed 
images from the three channels (Merge) it neither co-localises with the golgi apparatus nor 
mitochondria. In cells expressing GFP as a control, the protein distributed in the nucleus and 
cytoplasm. 
Figure 2. A) Endogenous TMCO1 protein in human optic nerve. Protein lysate from optic 
nerve tissue were analysed by Western blotting with the rabbit anti-TMCO1 antibody. The 
~21 kDa band corresponds with the expected size of the TMCO1 protein. Molecular sizes of 
the protein standards are indicated in kilodaltons (kDa). B) Immunolabelling of TMCO1 in 
the human eye. Paraffin sections of human eye were immunolabelled with the anti-TMCO1 
antibody and imaged by light microscopy. Positive immunolabelling can be seen as red signal 
in the A) iridocorneal angle, B, C) trabecular meshwork, D, E) ciliary body and F, G) retina. 
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Nuclei are stained blue. Pigment in panels A, C and E is marked by the letter ‘p’. 
Immunolabelling of TMCO1 as an intense spot in the nucleus can be seen in cells in the 
trabecular meshwork (C), ciliary body (E) and retina (G). Cytoplasmic immunolabelling is 
also visible in these tissues. Images are, A at 10×, B, D, F at 40× and C, E, G at 600×, original 
magnification. The presented results are representative of experiments on eyes from four 
independent donors. 
Figure 3. Immunolabelling of TMCO1 with nucleolin, coilin and SC35 in human retina. 
Confocal microscopy was performed on sections immunolabelled with anti-TMCO1 (green) 
antibody together with either anti-nucleolin, anti-coilin or anti-SC35 antibodies (red). Nuclei 
(blue) were stained with DAPI. Images from the three colour channels overlayed (merge) for 
determining co-localisation. Top row, TMCO1 localised to discrete regions in the nucleus co-
localises with nucleolin (highlighted by arrows). Middle row, TMCO1 does not co-localise 
with coilin (green and red separated in merged image). Bottom row, TMCO1 does not co-
localise with SC35 (green and red distinct in merged image). Scale bar: 5 µm. 
Figure 4. Immunolabelling of TMCO1 and nucleolin in human SH-SY5Y neuroblastoma 
cells. Confocal microscopy was performed on cells immunolabelled with the anti-TMCO1 
(green) and anti-nucleolin (red) antibodies. Nuclei (blue) were stained with DAPI. Images 
from the three colour channels overlayed (merge) for determining co-localisation. Top row, 
TMCO1 localised to discrete regions in the nucleus co-localises with nucleolin (yellow in 
merged image). Middle row, TMCO1 although localised to discrete regions in the nucleus 
does not completely co-localise with nucleolin (green and red somewhat separated in merged 
image). Bottom row, TMCO1 evenly distributed in the nucleus does not co-localise with 
nucleolin (green and red distinct in merged image). Images were taken with a 63× objective. 
Archived at Flinders University: dspace.flinders.edu.au
26 
 
Brightness and contrast of images in the bottom row were enhanced for improving visibility 
of the cytoplasmic signal.  
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Figure legends 
Figure 1. A) Fusion protein encoded by the GFP-TMCO1 construct. Cell lysates from HEK 
293A cells transiently transfected with the fusion construct (GFP-TMCO1) or pEGFP-C1 
vector (GFP) were analysed by Western blotting with the anti-GFP antibody. The band of 
approximately 50 kDa seen in the TMCO1-GFP lane corresponds with the expected size of 
the fusion protein and that of approximately 28 kDa in the GFP lane corresponds with the size 
of GFP. The >28 kDa protein band seen in the TMCO1-GFP lane may represent fusion 
protein degradation. Molecular sizes of the protein standards are indicated in kilodaltons 
(kDa). B) GFP-TMCO1 fusion localisation in SH-SY5Y human retinoblastoma cells. Cells 
transiently transfected with the fusion construct (GFP-TMCO1) or pEGFP-C1 vector (GFP) 
(green channel) were either stained with BODIPY-TR-Ceramide for labelling the golgi 
apparatus (Golgi) or MitoTracker® Red CM-H2XRos for labelling mitochondria (Mito) (red 
channel), nuclei counterstained with DAPI (blue channel), and visualised by confocal 
microscopy. GFP-TMCO1 can be seen in the cytoplasm (green). However, in overlayed 
images from the three channels (Merge) it neither co-localises with the golgi apparatus nor 
mitochondria. In cells expressing GFP as a control, the protein distributed in the nucleus and 
cytoplasm. 
Figure 2. A) Endogenous TMCO1 protein in human optic nerve. Protein lysate from optic 
nerve tissue were analysed by Western blotting with the rabbit anti-TMCO1 antibody. The 
~21 kDa band corresponds with the expected size of the TMCO1 protein. Molecular sizes of 
the protein standards are indicated in kilodaltons (kDa). B) Immunolabelling of TMCO1 in 
the human eye. Paraffin sections of human eye were immunolabelled with the anti-TMCO1 
antibody and imaged by light microscopy. Positive immunolabelling can be seen as red signal 
in the A) iridocorneal angle, B, C) trabecular meshwork, D, E) ciliary body and F, G) retina. 
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Nuclei are stained blue. Pigment in panels A, C and E is marked by the letter ‘p’. 
Immunolabelling of TMCO1 as an intense spot in the nucleus can be seen in cells in the 
trabecular meshwork (C), ciliary body (E) and retina (G). Cytoplasmic immunolabelling is 
also visible in these tissues. Images are, A at 10×, B, D, F at 40× and C, E, G at 600×, original 
magnification. The presented results are representative of experiments on eyes from four 
independent donors. 
Figure 3. Immunolabelling of TMCO1 with nucleolin, coilin and SC35 in human retina. 
Confocal microscopy was performed on sections immunolabelled with anti-TMCO1 (green) 
antibody together with either anti-nucleolin, anti-coilin or anti-SC35 antibodies (red). Nuclei 
(blue) were stained with DAPI. Images from the three colour channels overlayed (merge) for 
determining co-localisation. Top row, TMCO1 localised to discrete regions in the nucleus co-
localises with nucleolin (highlighted by arrows). Middle row, TMCO1 does not co-localise 
with coilin (green and red separated in merged image). Bottom row, TMCO1 does not co-
localise with SC35 (green and red distinct in merged image). Scale bar: 5 μm. 
Figure 4. Immunolabelling of TMCO1 and nucleolin in human SH-SY5Y neuroblastoma 
cells. Confocal microscopy was performed on cells immunolabelled with the anti-TMCO1 
(green) and anti-nucleolin (red) antibodies. Nuclei (blue) were stained with DAPI. Images 
from the three colour channels overlayed (merge) for determining co-localisation. Top row, 
TMCO1 localised to discrete regions in the nucleus co-localises with nucleolin (yellow in 
merged image). Middle row, TMCO1 although localised to discrete regions in the nucleus 
does not completely co-localise with nucleolin (green and red somewhat separated in merged 
image). Bottom row, TMCO1 evenly distributed in the nucleus does not co-localise with 
nucleolin (green and red distinct in merged image). Images were taken with a 63× objective. 
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Brightness and contrast of images in the bottom row were enhanced for improving visibility 
of the cytoplasmic signal.  
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